NICE

Cinacalcet – Appraisal Consultation Document (2)

1.1 Cinacalcet hydrochloride is not recommended for the routine treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy.

1.2 Cinacalcet hydrochloride is recommended only in those patients with refractory secondary hyperparathyroidism (including those with calciphylaxis):
   
   • who have 'very uncontrolled' plasma levels of intact parathyroid hormone (defined as greater than 85 pmol/litre [800 pg/ml]) that are refractory to standard therapy and
   
   • in whom surgical parathyroidectomy is contraindicated.
   
Response to treatment should be monitored regularly and treatment should be continued only if a reduction in the plasma level of intact parathyroid hormone of 30% or more is seen after 3 months' treatment.

Kidney Alliance Response

The Kidney Alliance welcomes the amendments to the recommendations regarding cinacalcet.

The Alliance is comfortable with 1.1 which recommends that the routine treatment of secondary hyperparathyroidism should continue as currently with the use of vitamin D preparations and phosphate binders – standard therapy.

The Alliance welcomes the recommendation to allow a trial of cinacalcet to those patients who's disease can no longer be controlled by standard therapy and in whom parathyroidectomy is contraindicated.

The Alliance believes that the recommendation could be improved if the word contraindicated was replaced by "in those patients in whom attempted parathyroidectomy is considered a last resort by the clinical team".

Given the logistics of PTH measurement and the need for incremental dosing the KA would welcome an extension of the “trial period” to 4 months.